BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rocha M, Correia de Sousa J, Salgado M, Araújo A, Pedroto I. Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor. GE Port J Gastroenterol 2019;26:268-74. [PMID: 31328141 DOI: 10.1159/000494569] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Kooshkaki O, Derakhshani A, Hosseinkhani N, Torabi M, Safaei S, Brunetti O, Racanelli V, Silvestris N, Baradaran B. Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. Int J Mol Sci 2020;21:E4427. [PMID: 32580338 DOI: 10.3390/ijms21124427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
2 Mendo R, Figueiredo P, Mascarenhas L. Checkpoint Inhibitor-Induced Gastroduodenitis: An Unusual Manifestation. GE Port J Gastroenterol 2021;28:150-2. [PMID: 33791404 DOI: 10.1159/000509196] [Reference Citation Analysis]
3 Vindum HH, Agnholt JS, Nielsen AWM, Nielsen MB, Schmidt H. Severe steroid refractory gastritis induced by Nivolumab: A case report. World J Gastroenterol 2020;26:1971-8. [PMID: 32390707 DOI: 10.3748/wjg.v26.i16.1971] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
4 Kichloo A, Albosta M, Dahiya D, Guidi JC, Aljadah M, Singh J, Shaka H, Wani F, Kumar A, Lekkala M. Systemic adverse effects and toxicities associated with immunotherapy: A review. World J Clin Oncol 2021;12:150-63. [PMID: 33767971 DOI: 10.5306/wjco.v12.i3.150] [Reference Citation Analysis]
5 Behravesh S, Shomali N, Danbaran GR, Aslani S, Hemmatzadeh M, Hosseinzadeh R, Gowhari-Shabgah A, Mohammadi H. Cardiotoxicity of immune checkpoint inhibitors: An updated review. Biotechnol Appl Biochem 2020. [PMID: 33289168 DOI: 10.1002/bab.2081] [Reference Citation Analysis]